Navigation Links
MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
Date:1/18/2008

Daiichi Sankyo, Inc. announced today that the United States Food and Drug Administration (FDA) has approved WelChol(R) (colesevelam HCl) Tablets as the first LDL cholesterol lowering medication also indicated for improving glycemic control in adults with type 2 diabetes mellitus (DM) in combination with metformin, sulfonylureas, or insulin, when these agents are used alone or in combination with other anti-diabetic agents.

The ADA estimates that 20.8 million people in the United States have diabetes and more than 90% of these have type 2 diabetes. People with diabetes face significantly higher risk of developing cardiovascular disease. It is estimated that approximately half of all Americans have elevated blood cholesterol levels that can negatively impact their health and quality of life. According to a recent Harris Interactive Survey, approximately 29% of adults previously diagnosed with hypercholesterolemia have also been diagnosed with diabetes. Given the prevalence of diabetes and high LDL cholesterol, a medication that can help lower both A1C and LDL cholesterol can be beneficial for many patients. Welchol is a new option that addresses these two chronic health conditions and provides physicians with a different therapeutic approach for treating patients with type 2 diabetes.
For more information, please visit http://www.dsus.com.

SATELLITE FEED:

Friday, January 18th, 2008

6:30 PM - 6:45 PM ET

Galaxy 25

C-Band

Transponder 14

Downlink Freq. 3980 Horizontal

Preview and access this video on Pathfire DMG: Slug # 29711

Search within the PR Newswire or MultiVu section by story ID # 29711 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: WelChol Receives FDA Approval To Reduce Blood Glucose in Adults with Type 2 Diabetes

FORMAT: B-roll and Soundbites.

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/29711/press.html

SOUNDBITES:

* Dr. Ronald B. Goldberg, Professor of Medicine and Professor,

Biochemistry and Molecular Biology at the University of Miami and the

Associate Director of the Diabetes Research Institute

B-ROLL INCLUDES:

* Doctor/Patient footage

* Patient lifestyle & footage

* Product shots/manufacturing footage

* Daiichi Sankyo exteriors

VIDEO PROVIDED BY: Daiichi Sankyo

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Photo: MultiVu Promotes George DeTorres to Divisional Vice President for the MultiVu Healthcare Team
2. MultiVu Video Feed: NEW SURVEY FINDS THAT HALF OF CAREGIVERS SPEND 10 PERCENT OF THEIR INCOME CARING FOR AN OLDER LOVED ONE
3. MultiVu Video Feed: STARLIGHT STARBRIGHT UNVEILS GET FIT, GET RIGHT A PROGRAM TO PREVENT TYPE 2 DIABETES AND WEIGHT-RELATED CONDITIONS IN TEENS
4. MultiVu Video Feed: Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With "Silence the Sounds of Pertussis" Campaign
5. MultiVu Video Feed: FDA Approves DORIBAX(TM) (doripenem for injection) for the Treatment of Complicated Intra-abdominal and Complicated Urinary Tract Infections
6. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
7. VIDEO from Medialink and The Leukemia & Lymphoma Society: Saving Lives One Mile at a Time
8. VIDEO from Medialink and Stryker: New Alternative to Hip Replacement Surgery
9. InfoLogix Featured in FOX Business News Interview on Reducing Healthcare Medication Errors - Video Available Online
10. VIDEO from Medialink and Revolution Health: RevolutionHealth.com Launches Resolutions 2.0
11. VIDEO from Medialink and GlaxoSmithKline: Really Think You Can Lose 30 Pounds in 30 Days?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... cream that’s the first in a new class of photodynamic cosmetics (PDC). , ... of skin, visibly reduce outward signs of aging, and minimize the appearance of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: